Comparative Pharmacology
Head-to-head clinical analysis: GRIS PEG versus MONISTAT 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRIS PEG versus MONISTAT 5.
GRIS-PEG vs MONISTAT 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by interfering with the polymerization of tubulin, thereby inhibiting fungal cell mitosis and nucleic acid synthesis.
Miconazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
For tinea capitis and other dermatophyte infections: 500 mg oral daily as a single dose or in divided doses. For more severe infections, up to 1 g daily in divided doses.
Miconazole nitrate 100 mg vaginal suppository inserted once daily at bedtime for 3 days; or 200 mg vaginal suppository once daily at bedtime for 3 days; or 1200 mg vaginal suppository as a single dose.
None Documented
None Documented
Terminal elimination half-life 14-24 hours. With continuous therapy, time to steady-state is ~3-5 days.
Terminal half-life approximately 24 hours; supports once-daily dosing.
Primarily renal (as glucuronide conjugates): ~80%; fecal/biliary: ~10-15%; unchanged drug <1%.
Primarily fecal (90%) as unchanged drug; renal excretion minimal (<1%).
Category C
Category C
Antifungal
Antifungal